Of note, a cell-specific approach may reduce adverse effects that could occur after TLR4 antagonist administration such as reduced neuronal survival and proliferation or the inhibition of phagocytosis by microglia, which is of extreme relevance in stroke pathology (41). This evidence concerns the gene TLR4 and stroke disorder.